Glassman Wealth Services’s Immunovant IMVT Stock Holding History

Glassman Wealth Services’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-300	Closed	-$11.5K	–	2024
2023 Q3	$11.5K	Buy	+300	New	+$6.78K	﹤0.01%	813

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Glassman Wealth Services's IMVT Position: Q4 2023 in Review

Glassman Wealth Services sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 300 shares — an estimated $11.5K sold.

Glassman Wealth Services first reported a position in IMVT in Q3 2023 and held it in 1 quarter. The position peaked at $11.5K in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

Glassman Wealth Services reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
Glassman Wealth Services sold 300 Immunovant shares in Q4 2023, an estimated $11.5K.
Glassman Wealth Services first reported a position in Immunovant in Q3 2023 and held it in 1 quarter.
Glassman Wealth Services's Immunovant position peaked at $11.5K in Q3 2023.
228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on Glassman Wealth Services's 13F filing for Q4 2023, filed 12 Feb 2024.